- Kenox Pharmaceuticals Inc. has expanded its analytical capabilities for orally inhaled and nasal drug products (OINDPs) by adding Laser Diffraction and SprayVIEW systems.
- The new systems enable testing for droplet size distribution, spray pattern, and plume geometry to support development, bioequivalence studies, and regulatory submissions.
Kenox Pharmaceuticals Inc. has expanded its analytical testing capabilities for orally inhaled and nasal drug products (OINDPs) by introducing Laser Diffraction and SprayVIEW systems for aerosol characterization. The upgrade enables testing of droplet size distribution (DSD), spray pattern (SP), and plume geometry (PG) under GMP-compliant conditions.
The company said the new equipment will support development and analytical evaluation of nasal and inhaled therapies. These testing capabilities are designed to provide detailed data on aerosol performance and support regulatory submissions and bioequivalence studies.
Kenox operates as a contract development and manufacturing organization (CDMO) focused on OINDPs and ophthalmic drug products. Its analytical platform supports programs from early development through commercial lifecycle management with validated methodologies aligned with FDA and EMA expectations.
The Laser Diffraction system measures droplet size distribution by analyzing light scattering as a laser passes through a spray plume, providing data on droplet size, atomization efficiency, and spray consistency. SprayVIEW technology supports spray pattern analysis using laser-sheet imaging to quantify spray area, ovality, and spatial distribution.
Plume geometry characterization evaluates plume width and plume angle at defined distances to assess atomization performance, formulation-device compatibility, and spray reproducibility. Kenox said these capabilities enable a comprehensive aerosol performance characterization package for nasal and inhaled drug development programs.
